| Metric | This Period | Prior Year Period | YoY |
|---|---|---|---|
| Revenue | ¥637.7B | ¥590.6B | +8.0% |
| Operating Income | ¥46.4B | ¥41.0B | +13.2% |
| Ordinary Income | ¥48.9B | ¥43.4B | +12.8% |
| Net Income | ¥33.3B | ¥31.4B | +6.0% |
| ROE | 2.2% | 2.0% | - |
For FY2027 Q1, Revenue was ¥637.7B (YoY +¥47.1B +8.0%), Operating Income was ¥46.4B (YoY +¥5.4B +13.2%), Ordinary Income was ¥48.9B (YoY +¥5.5B +12.8%), and Net Income was ¥33.3B (YoY +¥1.9B +6.0%), achieving both revenue and profit growth. Operating margin improved to 7.3% (up +0.4pt from 6.9% a year ago) as cost absorption progressed, enhancing profitability. The core Retail Business led growth with Revenue +8.0%, and the CVS Business also performed steadily at +7.0%. The larger increase in Operating Income relative to Net Income reflects an effective tax rate of 30.9% and tax burden remaining at prior-year levels; recurring profitability improvement is evident. Progress against the full-year plan was ahead of standard Q1 pacing: Revenue 24.8%, Operating Income 26.5%, Net Income 27.7%, indicating a smooth start.
[Revenue] Top line was ¥637.7B (+8.0%), with the Retail Business accounting for ¥613.7B (+8.0%) and representing 96.2% of Revenue. The CVS Business maintained high growth at ¥24.0B (+7.0%) and accounted for 3.8% of Revenue. Both segments benefited from increases in customer counts and average transaction value, achieving balanced growth. Gross margin was flat at 29.1% (prior year 29.1%), indicating stable product mix and pricing policy.
[Profitability] Operating Income was ¥46.4B (+13.2%), with SG&A ratio improving to 30.1% (down -0.1pt from 30.2% prior year). Absolute SG&A was ¥191.7B (+7.4%), growing less than Revenue and realizing scale benefits. Non-operating income was ¥2.7B (prior year ¥2.5B), contributed by dividend income ¥0.8B and interest income ¥0.5B, while non-operating expenses were limited at ¥0.2B. From Ordinary Income ¥48.9B, after deducting extraordinary losses ¥0.8B (loss on disposal of fixed assets), corporate taxes ¥14.9B, and attributable to non-controlling interests ¥2.7B, Net Income was ¥33.3B (+6.0%). Net margin was slightly down to 5.2% (from 5.3% prior year), driven by increased attributable non-controlling interests and relative tax burden. Conclusion: achieved revenue and profit growth.
The Retail Business posted Operating Income of ¥40.6B (+12.9%), a margin of 6.6%, combining revenue growth and efficiency improvement. It contributed 87.4% of Operating Income and is the company's earnings pillar. The CVS Business delivered Operating Income ¥5.8B (+15.6%), margin 24.3%, maintaining high margins and contributing 12.6% of Operating Income. CVS’s high-profit profile supports the company-wide Operating margin, and combined with Retail scale, establishes a stable earnings base.
[Profitability] Operating margin 7.3% (up +0.4pt from 6.9% prior year), Net margin 5.2% (down -0.1pt from 5.3% prior year). Operating-level efficiency is improving, while net profit stage shows slight decline due to tax and non-controlling interest impacts. ROE 2.2% (prior year 1.8%) is trending up but capital efficiency remains low.
[Cash Quality] Cash and deposits ¥538.9B (prior year ¥795.3B, -¥256.4B) decreased due to timing of working capital and shareholder returns. Days sales outstanding (DSO) 62 days (prior year 49 days), inventory days 143 days (prior year 153 days); longer receivable collection is pressuring working capital. Days payable outstanding (DPO) shortened materially to 124 days (prior year 204 days), indicating a change in settlement timing that is a headwind to Operating Cash Flow (OCF).
[Investment Efficiency] Tangible fixed assets ¥970.2B (prior year ¥965.9B) with restrained large-scale investment; intangible asset ratio 0.4% indicating conservatism. Total asset turnover 0.33x (annualized 1.3x) shows room for efficiency improvement.
[Financial Soundness] Equity Ratio 78.1% (prior year 74.1%) is high; Current Ratio 242.9% (prior year 220.4%), Quick Ratio 197.8% — liquidity is very ample. Interest-bearing debt is virtually zero and interest coverage is 774x, indicating no payment ability concerns.
While the cash flow statement is not disclosed, balance sheet movements indicate cash trends: Cash and deposits ¥538.9B (prior year ¥795.3B, -¥256.4B -32.2%) declined sharply. Accounts receivable increased to ¥109.2B (prior year ¥80.2B, +¥29.0B +36.1%), raising working capital demand via extended collection cycles. Accounts payable decreased to ¥137.1B (prior year ¥208.8B, -¥71.7B -34.3%), significantly lower, suggesting payments were made earlier due to changes in settlement timing. Inventories were ¥157.8B (prior year ¥156.5B) and largely stable, indicating generally good inventory control. Treasury stock increased to ¥68.1B (prior year ¥42.0B, +¥26.1B) reflecting shareholder returns. The cash decline appears to be the result of both working capital timing and share buybacks; liquidity remains ample and financing risk is limited.
Relative to Operating Income ¥46.4B, non-operating income ¥2.7B (0.4% of Revenue) comprised mainly of dividend income ¥0.8B and interest income ¥0.5B, indicating high quality of recurring earnings. Non-operating expenses ¥0.2B (interest expense ¥0.1B) are limited and financial cost pressure is minor. Extraordinary loss ¥0.8B (loss on disposal of fixed assets) is a one-off with limited impact on Net Income. The bridge from Ordinary Income ¥48.9B to Net Income ¥33.3B reflects taxes ¥14.9B (effective tax rate 30.9%) and attributable to non-controlling interests ¥2.7B, with no evident structural distortion. The divergence between OCF and Net Income is mainly due to working capital timing (accounts receivable increase / accounts payable decrease), and accrual quality is generally sound.
Full-year plan: Revenue ¥2,572.7B, Operating Income ¥175.3B (+2.7%), Ordinary Income ¥179.8B (+1.2%), Net Income ¥110.3B. Q1 progress rates were Revenue 24.8%, Operating Income 26.5%, Ordinary Income 27.2%, Net Income 27.7%, exceeding standard quarterly pacing (25%) and on track. CVS high margins and Retail efficiency improvements contributed to a +1.5pt beat on Operating Income. The likelihood of achieving the full-year plan is high, and there is upside potential depending on consumer trends in H2.
Dividend forecast is ¥0, maintaining no dividend. Treasury stock increased to ¥68.1B (prior year ¥42.0B, +¥26.1B), confirming ongoing share buybacks as a form of capital return. Given Net Income ¥33.3B, Cash and deposits ¥538.9B, and low leverage (D/E 0.0x), the company has ample capacity for shareholder returns. Future dividend policy is not specified, but if profit growth and working capital efficiency improve, resumption or increase of dividends is conceivable.
Working capital efficiency deterioration risk: DSO extended to 62 days (prior year 49 days, +13 days), DPO shortened to 124 days (prior year 204 days, -80 days), worsening the cash conversion cycle. Looser collection terms or changes in settlement timing are pressuring OCF, raising concern that cash generation could lag during a revenue growth phase. While inventory days improved to 143 days, resolving the receivable/payable timing gap is urgent.
Segment concentration risk: Retail accounts for 96.2% of Revenue and 87.4% of Operating Income; poor performance in the core segment would directly affect overall results. Although CVS is high-margin and growing, its 3.8% share of Revenue is limited and provides little diversification. Intensifying retail competition or e-commerce displacement of existing-store sales could pressure company-wide earnings.
Low capital efficiency: ROE 2.2% may be below cost of capital, posing shareholder value creation challenges. Total asset turnover 0.33x (annualized 1.3x) is low; improving operating margin alone may be insufficient to materially boost shareholder returns. M&A or more efficient CAPEX and working capital compression to improve ROIC will be key, but short-term improvement is difficult to foresee.
Profitability & Return
| Metric | Company | Median (IQR) | Delta |
|---|---|---|---|
| Operating Margin | 7.3% | 3.4% (0.8%–7.7%) | +3.9pt |
| Net Margin | 5.2% | 2.2% (0.5%–6.2%) | +3.0pt |
Both Operating and Net Margins are well above industry medians, placing the company in the upper tier on profitability.
Growth & Capital Efficiency
| Metric | Company | Median (IQR) | Delta |
|---|---|---|---|
| Revenue Growth (YoY) | 8.0% | 7.7% (0.8%–14.6%) | +0.3pt |
Revenue growth is in line with the industry median; growth is at an industry-standard level.
※ Source: Company compilation
Structural profitability advantage and steady full-year progress: Operating margin 7.3% exceeds the industry median 3.4% by +3.9pt, confirming competitive advantage leveraging CVS high margins (24.3%) and Retail scale. Progress vs. full-year plan (Operating Income 26.5%, Net Income 27.7%) exceeds standard pacing, leaving room for upward revision depending on H2 consumption. If gross margin stability at 29.1% and SG&A restraint continue, recovery to the 8% range in Operating margin is plausible.
Working capital and capital efficiency improvement are key to valuation: DSO +13 days, DPO -80 days have worsened the cash conversion cycle. ROE 2.2% and total asset turnover 0.33x are low within the industry; high profitability has not fully translated into shareholder returns. Normalizing settlement terms, improving inventory turns, and boosting asset efficiency (store refurbishments, review of low-efficiency assets) would directly restore OCF and improve ROIC, thereby enhancing shareholder value — but short-term improvement is uncertain.
This report was automatically generated by AI analyzing XBRL financial statement data to produce a financial analysis document. It does not constitute a recommendation to invest in any specific security. Industry benchmarks are reference information compiled by the firm from public financial statements. Investment decisions are your responsibility; consult a professional advisor as needed before acting.